MedTrace Logo

PMCF Study of Precise Pro Rx for Carotid Artery Disease

NCT07204678 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2026-03-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate long-term clinical safety and performance of the PRECISE PRO RX Nitinol Stent System to treat stenotic lesions of the carotid arteries.

Conditions

  • Carotid Artery Stenosis

Interventions

DEVICE

PRECISE PRO Rx Nitinol Stent System

The Cordis PRECISE PRO Rx Nitinol Stent System is a single-use device consisting of an endovascular stent and sheath delivery system, intended to deliver a self-expanding endovascular stent to the carotid artery(ies). The stent component imparts an outward radial force on the luminal surface of the vessel wall restoring vascular patency. The Cordis PRECISE PRO Rx Nitinol Stent System is indicated for use in patients with stenotic lesions of the carotid artery(ies).

Sponsors & Collaborators

  • Rede Optimus Hospitalar SA

    collaborator NETWORK

  • Cordis US Corp.

    lead INDUSTRY

Principal Investigators

  • Nusrath Sultana · Cordis US Corp.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2026-02-27
Completion
2026-02-27
FDA Device
Yes

Countries

  • Austria
  • France
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07204678 on ClinicalTrials.gov